Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Litzenburger T, Steffgen J, Benediktus E, Müller F, Schultz A, Klein E, Ramanujam M, Harcken C, Gupta A, Wu J, Wiebe S, Li X, Flack M, Padula SJ, Visvanathan S, Hünnemeyer A, Hui J. Litzenburger T, et al. Among authors: flack m. Br J Clin Pharmacol. 2021 Apr;87(4):1824-1838. doi: 10.1111/bcp.14571. Epub 2020 Nov 20. Br J Clin Pharmacol. 2021. PMID: 32986868 Free PMC article. Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Papp KA, et al. Among authors: flack m. N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. N Engl J Med. 2017. PMID: 28423301 Free article. Clinical Trial.
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S, Baum P, Vinisko R, Schmid R, Flack M, Lalovic B, Kleiner O, Fuentes-Duculan J, Garcet S, Davis JW, Grebe KM, Fine JS, Padula SJ, Krueger JG. Visvanathan S, et al. Among authors: flack m. J Allergy Clin Immunol. 2019 Jun;143(6):2158-2169. doi: 10.1016/j.jaci.2018.11.042. Epub 2018 Dec 20. J Allergy Clin Immunol. 2019. PMID: 30578873 Free article. Clinical Trial.
The Effect of BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma t Antagonist, Bevurogant) on the Pharmacokinetics of a Transporter Probe Cocktail, Including Digoxin, Furosemide, Metformin, and Rosuvastatin: An Open-Label, Non-randomized, 2-Period Fixed-Sequence Trial in Healthy Subjects.
Choi H, Huang F, Flack M. Choi H, et al. Among authors: flack m. Clin Pharmacol Drug Dev. 2024 Feb;13(2):197-207. doi: 10.1002/cpdd.1344. Epub 2023 Nov 13. Clin Pharmacol Drug Dev. 2024. PMID: 37960990
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Blauvelt A, et al. Among authors: flack m. JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723. JAMA Dermatol. 2020. PMID: 32267471 Free PMC article. Clinical Trial.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Reich K, et al. Among authors: flack m. Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Lancet. 2019. PMID: 31280967 Clinical Trial.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Among authors: flack m. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
68 results